List of Excipients in Branded Drug BUDEPRION XL

Generic Drugs Containing BUDEPRION XL

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY Inc dba Vangard Labs	bupropion hydrochloride	0615-7560	ALCOHOL
NCS HealthCare of KY Inc dba Vangard Labs	bupropion hydrochloride	0615-7560	ETHYLCELLULOSE
NCS HealthCare of KY Inc dba Vangard Labs	bupropion hydrochloride	0615-7560	HYDROCHLORIC ACID
NCS HealthCare of KY Inc dba Vangard Labs	bupropion hydrochloride	0615-7560	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in BUDEPRION XL?

# Of NDCs	Excipient
1	ALCOHOL
1	ETHYLCELLULOSE
1	HYDROCHLORIC ACID
1	HYDROXYPROPYL CELLULOSE

Budeprion XL Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Budeprion XL is a discontinued extended-release formulation of bupropion hydrochloride, an aminoketone antidepressant also used for smoking cessation. Its commercial opportunity is no longer based on originator exclusivity. The value lies in developing a technically robust bupropion XL product with reliable dissolution, lower formulation risk, competitive manufacturing cost, and a clear regulatory pathway.

The main formulation lesson is the 2012 FDA finding that Budeprion XL 300 mg was not therapeutically equivalent to Wellbutrin XL 300 mg because it released bupropion more rapidly and produced different systemic exposure in some patients. The issue increased scrutiny of release-controlling excipients, scale-up, dissolution testing, and dose proportionality for bupropion extended-release tablets.[1]

What is Budeprion XL and how was it regulated?

Budeprion XL was an extended-release tablet containing bupropion hydrochloride. The product was approved through the abbreviated new drug application pathway as a generic equivalent to Wellbutrin XL.

Attribute	Budeprion XL
Active ingredient	Bupropion hydrochloride
Dosages	150 mg and 300 mg extended-release tablets
Therapeutic categories	Major depressive disorder; smoking cessation class through bupropion
Dosage form	Once-daily oral extended-release tablet
Reference product	Wellbutrin XL
Regulatory pathway	Abbreviated New Drug Application
Key regulatory issue	FDA determination that the 300 mg product was not therapeutically equivalent to Wellbutrin XL 300 mg
Current commercial status	Historical product; no meaningful current brand exclusivity
Biosimilar relevance	None; bupropion is a small-molecule drug
Main development risk	Reproducing the reference product’s in vivo and in vitro release profile

Budeprion XL 300 mg was withdrawn from the market after FDA concluded that the product did not demonstrate equivalent bioavailability to Wellbutrin XL 300 mg. FDA reported that Budeprion XL 300 mg released bupropion more rapidly, resulting in higher peak concentrations and lower exposure during part of the dosing interval.[1]

The FDA later required stronger comparative studies for certain bupropion extended-release products. The regulatory precedent applies broadly to modified-release generic development, particularly where small changes in excipient grade, coating weight, tablet hardness, or manufacturing scale can change pharmacokinetics.

What excipients were used in Budeprion XL?

Budeprion XL used a matrix and coating-based extended-release design. Public product labeling identifies inactive ingredients used in the tablet and film coating, although exact excipient identity and grade can vary by strength, manufacturing site, and approved labeling revision.[2]

Relevant excipient functions include:

Excipient function	Typical material classes	Formulation role
Release control	Hypromellose, ethylcellulose or related polymers	Controls water penetration and drug diffusion
Matrix structure	Hydrophilic polymer, waxy lipid, or polymer-lipid combination	Establishes the extended-release profile
Binder	Povidone or related binder	Provides granule and tablet cohesion
Lubricant	Magnesium stearate, stearic acid, or related lubricant	Controls ejection and tooling friction
Glidant	Colloidal silicon dioxide	Improves powder flow and content uniformity
Film coating	Hypromellose, plasticizer, pigment, opacifier	Protects the tablet and controls surface properties
Colorant	Approved mineral or synthetic pigment	Supports product identification
Processing aid	Water or volatile solvent removed during processing	Enables granulation or coating

The commercial risk is not limited to the named excipient. Polymer viscosity grade, particle-size distribution, substitution level, moisture content, granulation endpoint, coating permeability, and lubricant concentration can materially affect release.

For bupropion XL, excipient strategy must be treated as a release-engineering program rather than a simple inactive-ingredient substitution exercise.

Which excipients control bupropion XL release?

Hydrophilic polymers

Hypromellose is widely used in extended-release matrix tablets. After hydration, it forms a gel layer that controls penetration of gastrointestinal fluid and diffusion of dissolved drug. Polymer viscosity and loading level affect the gel strength and release rate.

A higher-viscosity grade generally produces a stronger gel and slower release, although the relationship is product-specific. Polymer particle size, distribution through the blend, and compaction behavior also affect performance.

Hydrophobic polymers and waxes

Ethylcellulose and waxy excipients can reduce water ingress and create a more diffusion-limited system. They can also reduce sensitivity to certain compression variables when properly distributed.

Hydrophobic release control may be attractive for bupropion because it can reduce rapid liberation of drug from the tablet. The risk is incomplete release, food-effect sensitivity, or excessive variability after scale-up.

Binders and lubricants

Povidone and similar binders influence granule density and porosity. Magnesium stearate and stearic acid can create hydrophobic surfaces when over-lubrication occurs. Excessive blending time or lubricant concentration may slow dissolution and increase batch variability.

This is a critical control point because two formulations with the same qualitative excipient list can have different release profiles due to different process conditions.

Film-coating systems

A conventional film coat primarily protects the tablet and supports identification. It can still influence early dissolution if the coating is dense, highly hydrophobic, or inadequately perforated.

A functional coating can provide an additional release-control mechanism, but it increases process complexity, coating uniformity requirements, and regulatory comparability burden.

What excipient strategy is most commercially attractive?

The strongest strategy is a robust hydrophilic or polymer-lipid matrix that achieves the reference profile with a narrow manufacturing design space. The target should be reliable performance across:

• 150 mg and 300 mg strengths;
• fed and fasted conditions;
• different tablet hardness levels;
• normal manufacturing-scale variation;
• relevant dissolution media and agitation conditions;
• accelerated and long-term stability;
• packaging configurations used in commercial distribution.

A commercial formulation should avoid unnecessary excipient complexity. Each additional polymer, coating layer, or processing step increases cost and creates another source of variability.

Preferred development architecture

A practical development program would compare three architectures:

Architecture	Advantages	Commercial disadvantages
Hydrophilic matrix tablet	Low cost, conventional equipment, scalable	Sensitive to polymer grade, compression, and dissolution method
Polymer-lipid matrix	Strong release control, potentially lower burst risk	More complex blending and scale-up
Coated matrix or reservoir system	Greater release-profile flexibility	Higher manufacturing cost and stronger process-control burden

A hydrophilic matrix is likely to provide the lowest-cost platform. A polymer-lipid system may provide a better technical margin if the target dissolution profile is difficult to reproduce using hypromellose alone.

What formulation patents protect bupropion XL?

The historic Wellbutrin XL patent estate covered extended-release bupropion formulations and related dosage-form technology. Those patents did not create a durable current barrier to generic development because the principal U.S. patent protection has expired or no longer provides practical market exclusivity for a new bupropion XL entrant.[3]

The main current protection opportunities are therefore new patents directed to:

• specific polymer ratios;
• defined dissolution profiles;
• reduced food-effect formulations;
• alcohol-resistant release systems;
• low-variability manufacturing processes;
• tablet architecture and coating combinations;
• moisture-resistant packaging;
• improved stability under high humidity;
• multiparticulate or sprinkle-compatible dosage forms;
• abuse-deterrent or tamper-resistant systems;
• clinically relevant pharmacokinetic performance.

A formulation patent must contain more than a conventional list of excipients. Patent value will depend on whether the claimed combination produces an unexpected release profile, improved pharmacokinetic consistency, reduced dose dumping, or a clinically relevant manufacturing advantage.

A patent directed only to replacing one standard polymer with another is likely to face obviousness challenges unless supported by comparative data.

When does Budeprion XL lose exclusivity?

Budeprion XL has no meaningful remaining product-specific exclusivity that would block a new generic bupropion extended-release filing. The product’s commercial relevance is historical, while bupropion XL remains a mature generic market.

Exclusivity category	Budeprion XL position
New chemical entity exclusivity	Not applicable
Orphan exclusivity	Not applicable
Pediatric exclusivity	No current product-specific barrier identified
Reference-product exclusivity	Expired
Orange Book patent barrier	No current Budeprion-specific barrier expected to prevent generic entry
Biosimilar exclusivity	Not applicable
Generic regulatory path	ANDA, subject to reference-product and equivalence requirements

The key distinction is between patent expiry and regulatory approval risk. Expired patents reduce legal barriers, but they do not eliminate the technical requirement to demonstrate bioequivalence to the FDA-designated reference product.

What is the Orange Book status of Budeprion XL?

Budeprion XL is not the active reference product for the market. FDA’s Orange Book framework identifies reference-listed drugs, therapeutic-equivalence codes, patents, and exclusivity. For current bupropion hydrochloride extended-release development, the relevant comparator is the FDA-designated reference product for the applicable strength and dosage form, not simply a discontinued historical generic.[4]

The practical implications are:

1. A developer must identify the current reference-listed drug and approved reference product.
2. The applicant must confirm the applicable product-specific guidance.
3. The formulation must meet current FDA expectations for bioequivalence and dissolution.
4. Historical Budeprion XL data should be used as a risk signal, not as a development target.
5. Any listed patents for current reference products must be reviewed through the Paragraph IV process.

Are Paragraph IV challenges relevant to bupropion XL?

Paragraph IV challenges remain legally possible if a current reference product has unexpired Orange Book patents. The commercial value of such a challenge is limited by the age of the molecule and the number of existing generic manufacturers.

A new applicant could pursue:

• a standard ANDA with Paragraph III certification where applicable;
• a Paragraph IV certification against any unexpired listed patent;
• a section viii statement for patents directed to an indication not being pursued;
• a formulation-specific 505(b)(2) strategy if the product differs materially from the approved reference product.

The strongest legal position would combine a non-infringement or invalidity argument with a formulation that does not rely on the patented feature. A formulation patent covering a new bupropion XL architecture could support later-stage licensing or settlement value, but only if the claim scope is technically defensible and commercially relevant.

What litigation affected Budeprion XL?

The principal regulatory controversy was the FDA’s bioequivalence determination, not a sustained patent dispute. FDA concluded in 2012 that Budeprion XL 300 mg was not therapeutically equivalent to Wellbutrin XL 300 mg. The agency attributed the issue to differences in release and exposure between the products.[1]

The case has continuing commercial significance because it demonstrates that:

• a generic can pass initial approval requirements and later face therapeutic-equivalence reassessment;
• a 300 mg strength may not be safely bridged from a 150 mg strength without adequate dose-proportionality evidence;
• dissolution similarity does not automatically establish clinical equivalence if the dissolution method lacks discriminatory power;
• manufacturing changes can create regulatory exposure after launch.

A new sponsor should conduct post-approval change planning before launch. The control strategy should link critical material attributes to critical process parameters and clinical performance.

What generic entry risks exist for a new bupropion XL product?

The main risks are technical and commercial.

Technical risks

The highest-risk areas are:

• rapid initial release, or burst release;
• excessive sensitivity to food;
• dose non-proportionality between 150 mg and 300 mg;
• failure under alcohol or high-solvent conditions;
• variability caused by tablet hardness or coating weight;
• incomplete release at later dissolution time points;
• stability-related changes in polymer hydration or tablet porosity;
• failure to reproduce the reference pharmacokinetic profile.

Bupropion has an active metabolite, hydroxybupropion, and its pharmacokinetic behavior must be considered in the bioequivalence program. Parent-drug data alone may not provide an adequate commercial risk assessment.

Commercial risks

Bupropion XL is a mature generic category with established suppliers. Price competition can be severe, particularly for the 150 mg and 300 mg strengths. A new product needs a cost or supply advantage rather than a nominally different excipient profile.

Potential differentiators include:

• fewer raw materials;
• direct compression with lower process complexity;
• improved stability in standard high-density polyethylene bottles;
• lower tablet weight;
• reduced coating time;
• lower batch-failure risk;
• reliable supply of critical polymers;
• dual-source excipient qualification;
• contract-manufacturing compatibility.

How strong is the patent estate for a new Budeprion XL formulation?

A new formulation patent estate could be moderately valuable if it protects a measurable technical advantage. It would be weak if it merely claims routine excipient substitutions.

Stronger claim themes

• defined release over multiple pH conditions;
• reduced peak-to-trough fluctuation;
• reduced food-effect sensitivity;
• resistance to alcohol-induced dose dumping;
• reproducible release across compression-force ranges;
• improved stability after moisture exposure;
• multiparticulate delivery with clinically demonstrated performance;
• a manufacturing process tied to a critical release attribute.

Weaker claim themes

• broad claims to bupropion plus a conventional polymer;
• claims covering routine coating materials;
• claims lacking comparative dissolution or pharmacokinetic data;
• claims that read directly on well-known Wellbutrin XL technology;
• narrow process claims that competitors can avoid through routine changes.

A layered portfolio is preferable. The sponsor should seek composition claims, dosage-form claims, process claims, and, where supportable, method-of-use claims directed to a differentiated product profile.

What formulation opportunities exist beyond conventional tablets?

Sprinkle or administration-flexible formulations

An extended-release formulation compatible with sprinkling on soft food could target patients with swallowing difficulty. The formulation must preserve release characteristics after opening, mixing, and administration.

This opportunity has technical value but also increases regulatory complexity. The sponsor would need to address dose uniformity, storage after opening, food compatibility, and the risk that a patient chews the dosage form.

Abuse-deterrent formulations

Bupropion is not an opioid, so FDA’s formal opioid abuse-deterrence framework does not directly apply. A tamper-resistant or crush-resistant formulation could still have value, but the commercial opportunity is less certain than for controlled substances.

A sponsor should avoid expensive abuse-deterrence technology unless it produces a measurable benefit in handling, safety, or institutional use.

Alcohol-resistant release

Alcohol-induced dose dumping is a useful formulation-screening endpoint. A polymer-lipid matrix or robust coating could provide differentiation if it maintains an acceptable release profile in alcohol-containing media without creating excessive incomplete release in standard media.

Pediatric or geriatric presentations

Bupropion XL is not readily suited to conventional liquid delivery because extended release can be lost when the dosage form is crushed or dispersed. A multiparticulate product could open a broader administration opportunity, but it would require extensive performance and labeling work.

How does Budeprion XL compare with Wellbutrin XL and other bupropion products?

Product category	Release profile	Main commercial position	Key formulation issue
Wellbutrin XL	Once-daily extended release	Originator benchmark	Reference dissolution and pharmacokinetic profile
Budeprion XL	Historical once-daily extended release	Discontinued or no longer commercially central	FDA-identified 300 mg bioequivalence failure
Generic bupropion XL	Once-daily extended release	Price-driven multisource market	Consistent equivalence and manufacturing cost
Wellbutrin SR	Twice-daily sustained release	Older modified-release segment	Different release target and dosing schedule
Bupropion immediate release	Multiple daily dosing	Low-cost mature product	Higher dosing frequency and peak exposure
Smoking-cessation bupropion products	Usually sustained release	Separate indication and branding	Labeling, dosing, and indication positioning

A new XL product should not be developed as a simple copy of the historical Budeprion design. Wellbutrin XL remains the relevant performance benchmark, while the 2012 Budeprion event identifies failure modes to avoid.

What licensing opportunities exist for bupropion XL excipient technology?

Licensing opportunities are most credible in three areas:

1. Release-control platforms. A polymer-lipid matrix with demonstrated alcohol resistance, stable dissolution, and scale-up data could be licensed to generic manufacturers.
2. Manufacturing technology. A low-cost process that reduces coating time, rejects, or dissolution variability could support a platform license.
3. Administration-flexible products. A validated sprinkle or multiparticulate technology could support a 505(b)(2) or differentiated generic strategy.

A license should be structured around measurable technical deliverables. Useful diligence metrics include:

• comparative dissolution against the reference product;
• pilot and commercial-scale batch data;
• bioequivalence results;
• stability through at least accelerated conditions;
• freedom-to-operate analysis;
• critical excipient supply agreements;
• patent term and geographic coverage;
• transferability to the licensee’s equipment.

What geographic markets offer commercial potential?

The United States is attractive because bupropion XL has a large established patient population and a defined ANDA framework. It is also highly competitive and exposed to generic price erosion.

Europe and other regulated markets may offer opportunities for products that satisfy local modified-release bioequivalence requirements, but the reference product, dossier requirements, naming conventions, and patent status differ by country.

Emerging markets may favor lower-cost formulations and local manufacturing. The primary barriers are often registration quality, excipient supply, analytical capability, and distribution rather than patent infringement.

A global strategy should separate:

• U.S. ANDA development;
• European decentralized or centralized regulatory planning where applicable;
• local patent and data-exclusivity review;
• excipient compliance under regional pharmacopeias;
• manufacturing-site qualification;
• serialization and packaging requirements.

What revenue exposure and market opportunity exist?

No current Budeprion XL-branded revenue stream should be assumed. The opportunity is the broader bupropion XL generic market.

Revenue potential depends on:

• number of approved competitors;
• payer contracts;
• wholesaler access;
• shortage or supply-disruption conditions;
• manufacturing cost per tablet;
• approved pack sizes;
• launch timing;
• ability to maintain supply;
• 150 mg and 300 mg portfolio coverage.

The 300 mg strength may offer higher unit demand in some channels, but it also carries greater technical and regulatory risk because the historic Budeprion issue was concentrated on the 300 mg product.

A dual-strength launch is commercially preferable only if the sponsor can demonstrate dose proportionality, comparable release behavior, and reliable supply. Otherwise, a staged launch beginning with the technically lower-risk strength may reduce exposure, although it can weaken contracting leverage.

Key Takeaways

• Budeprion XL is a historical bupropion hydrochloride extended-release product with no meaningful current brand exclusivity.
• Its main commercial lesson is the FDA’s 2012 finding that Budeprion XL 300 mg was not therapeutically equivalent to Wellbutrin XL 300 mg.
• Excipient grade, polymer loading, lubrication, tablet porosity, coating, and manufacturing scale can materially alter release.
• A new product should target the current FDA reference product, not replicate the historical Budeprion formulation.
• The strongest commercial formulation is likely a low-complexity matrix system with a wide manufacturing design space.
• Patent value will depend on demonstrated technical advantages, including reduced food effect, alcohol resistance, improved stability, or lower release variability.
• The opportunity is generic-market participation, not recovery of Budeprion XL brand revenue.
• The primary barriers are bioequivalence, formulation reproducibility, price competition, and reliable manufacturing.

FAQs

Can a company still launch a new Budeprion XL product?

A company can pursue a bupropion hydrochloride extended-release product through the applicable generic pathway, but it would not normally market the product as Budeprion XL without appropriate trademark rights and regulatory compliance. The relevant development target is the current FDA reference-listed drug.

Is bupropion XL suitable for an abuse-deterrent formulation?

It can be technically modified to resist crushing or alcohol-induced dose dumping, but the commercial case is less established than for opioid products. The investment should be supported by a defined handling, safety, or institutional-use benefit.

Which excipient is most important in a bupropion XL tablet?

The release-controlling polymer system is usually the most important excipient component. Its grade, concentration, distribution, hydration behavior, and interaction with compression and lubrication conditions can determine the dissolution profile.

Can a 150 mg bupropion XL formulation be scaled directly to 300 mg?

No. The higher strength requires independent evaluation of dose proportionality, tablet geometry, release behavior, mechanical properties, and pharmacokinetics. The historical Budeprion 300 mg issue shows why strength bridging requires specific evidence.

Does bupropion XL have biosimilar competition?

No. Bupropion is a small-molecule drug. Competition proceeds through generic drug pathways such as ANDAs, not biosimilar applications.

References

1. U.S. Food and Drug Administration. (2012). Update: Bupropion hydrochloride extended-release 300 mg bioequivalence. FDA Drug Safety Communication.

2. DailyMed. (n.d.). Budeprion XL: Bupropion hydrochloride extended-release tablets, prescribing information. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. U.S. Food and Drug Administration. (2024). Product-specific guidance documents for generic drug development. FDA Center for Drug Evaluation and Research.